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Abstract 
Background: The transplantation of porcine islet cells provides a new potential therapy to treat patients with type 1 
diabetes mellitus (T1DM). Compared to other biomedical technologies, xenotransplantation stands out in terms of its 
involvement of animals as graft sources, as well as the possible transmission of infectious diseases. As these aspects 
are especially relevant for potential xenotransplantation recipients, it is important to assess their opinion regarding 
this technology, in particular in terms of the requirements that should  be met in the informed consent process for  
xenotransplantation.
Methods: We conducted qualitative interviews with seven T1DM patients to assess their information needs prior 
to xenotransplantation. Before the interview, the participants received a model informed consent form for a clinical 
trial with porcine islet cells transplantation. The interviews were transcribed and analysed using qualitative content 
analysis.
Results: In the interviews, we identified several requirements that are crucial for patients with T1DM in order to 
consider xenotransplantation as a potential treatment option: therapy-related requirements, professional care and 
supervision, successful behaviour and attitude management, improving quality of life, and managing control/self-
determination challenges. Regarding the informed consent form, several of the participants’ questions remained open 
and should be addressed in more detail. The interviewees stressed the importance of personal consultations.
Conclusions: To become a sustainable therapeutic option, patients especially expected an improved diabetes 
control and a reduction of diabetes-related burdens. Health-related aspects prove to be pivotal for diabetic patients 
when considering porcine islet cell transplantation. The use of pigs as source for organ retrievals was not considered 
as problematic.
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Background
Xenotransplantation differs from other biomedical 
therapies especially in two respects. First, as animals 
are used to provide organs, tissues or cells, the question 
arises which role animals shall play in our society and if 
it can be ethically justified to use them as a source for 
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organ-replacement therapies. Second, xenotransplanta-
tion bears the small, but not completely excludable risk of 
the transmission of viruses from animals to the recipient. 
The risk of infectious diseases makes xenotransplanta-
tion a relevant issue also to people beyond the xeno-
graft recipient. This peculiarity of xenotransplantation is 
reflected in the ethical literature, also regarding its rele-
vance for informed consent to xenotransplantation thera-
pies [1–4]. As any member of society is potentially at risk 
of acquiring a xenogeneic infection, the informed con-
sent of the patient who shall receive the xenograft is not 
enough: xenotransplantation becomes a societal matter 
[1]. Hence, a “collective informed consent” [2] or a “com-
munity consent” [5] have been suggested. As the commu-
nity at risk is the global community, xenotransplantation 
also becomes a matter of global justice [3, 6].
However, for potential xenotransplantation candidates, 
more practical aspects are of primary interest [7]. They 
are concerned with questions regarding how a xenograft 
will affect their well-being, identity and self-perception, 
as well as how others will perceive them, including fear 
of stigmatisation. In addition, the effects on partners and 
family have to be considered. Besides these psychoso-
cial aspects, patients have a high interest in maintaining 
a good quality of life and reduce the diabetes-associated 
burden.
Among the various types of xenotransplantation, the 
transplantation of islet cells is the only form of cell or 
tissue transplantation that has seen clinical implementa-
tions [8, 9]. As it is likely that Germany will see its first 
islet xenotransplantation within the near future, we have 
chosen to interview potential candidates, i.e. patients 
with T1DM, to assess their attitudes to this potential 
therapy.
Before presenting and discussing the results of the 
interview study, we shall give an overview of socio-
empirical studies with potential and actual patients of 
islet cell xenotransplantation, followed by a brief review 
of the literature about informed consent in xenotrans-
plantation cases.
Attitudes and opinions of potential and actual xenograft 
recipients
Several studies have examined the views of diabetes 
patients who qualify as potential recipients of islet cell 
xenotransplantation on this potential diabetes therapy. 
There have been a few surveys and one interview study 
with potential xenograft recipients and two interview 
studies with actual xenotransplantation patients. All 
study participants were T1DM patients.
Among the participants of a survey study with diabe-
tes patients (type 1 and 2), 79% would accept the trans-
plantation of porcine islet cells [10]. Of those, 40% could 
imagine facing psychological problems due to having 
porcine cells in their body. Another survey with T1DM 
patients reported an acceptance rate of 52% [11]. How-
ever, a majority (70.5%) opted against xenotransplanta-
tion when they learned about the potential transmission 
of unknown diseases, the risks of immunosuppression, 
and that the transplantation might not result in complete 
insulin independence.
A questionnaire study about four alternative thera-
pies for diabetes was conducted among 85 patients with 
T1DM [12]. In addition to islet cell xenotransplanta-
tion, allogeneic islet transplantation, DNA vaccination, 
and induced pluripotent stem cell therapy (IPS) were 
presented. The preferred treatment was IPS (77.3%), 
followed by allogeneic islet transplantation (54.3%), 
xenotransplantation ranked third (52.2%) before DNA 
vaccination (41.3%). The participants reported the pros-
pect of being insulin independent as the most important 
motivator for accepting a new therapy, ahead of avoiding 
hypoglycaemia.
A recent study among 47 patients with T1DM with a 
similar research design compared several forms of allo-
geneic islet transplantation, IPS and (multiple and single) 
islet xenotransplantation [13]. While 83.3% of the partici-
pants would accept IPS, 66.7% would accept single and 
46.3% multiple xenotransplantation. The single encap-
sulated form of allogeneic islet transplantation received 
the highest acceptance rate of 50%. Again, the majority of 
patients aimed to become independent of insulin. At the 
same time, many opted against multiple transplantations.
In a survey with a total of 84 patients from a transplan-
tation outpatient clinic, 65% would accept a xenograft 
[14]. The acceptance rate among the 27 T1DM patients 
from this cohort was 85%. 66.7% could imagine the trans-
plantation of porcine islet cells. The majority expressed 
concerns regarding the transmission of diseases or 
genetic material, the side effects of immunosuppression, 
psychological stress, and third-party perception.
The variable results of the surveys may have been 
caused by differences in the research design and (the 
wording of ) the questions asked, the information given 
beforehand, etc. Also regional or cultural differences may 
be at play, as well as sociodemographic factors like age, 
educational level, or income. Independent of the underly-
ing disease, the severity of the disease, risk assessment, 
and compromised quality of life are major factors in 
determining patients’ attitudes [15].
In an interview study with nine T1DM patients with 
renal failure, the source of the transplant (whether 
human or animal) hardly played a role [16]. Of primary 
importance was the functionality of the graft. The priori-
ties of these patients may be related to the progression 
and severity of their diabetes, which has led to secondary 
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complications. At this stage of the disease, the source of a 
potential transplant becomes less relevant.
While there have been a few clinical studies with por-
cine islet cell transplantations [17], only two have exam-
ined issues beyond the medical field. In Sweden, eight 
patients with diabetes and kidney transplantation were 
injected with porcine foetal islets between 1990 and 
1993 [8]. Sarah Lundin examined the experiences of the 
islet recipients [18–20]. As survival was the priority for 
the recipients, other considerations became second-
ary. Hence, they found various ways to justify the use of 
animal transplants [18, 19]. Patients have “the desire to 
be healthy, natural, and normal” and for that purpose 
they are willing to accept an “unnatural technique”[20]. 
Some transplant patients also felt pressure regarding the 
“technological imperative”, i.e. having to seek biotech-
nological treatment in case one exists [19, 20]. Never-
theless, patients reported feeling uneasy about crossing 
“boundaries of nature” [18]. Given the fluidity of the cells, 
the recipients did not know where they were, whether 
they were still in the body, and what they were or may be 
doing. This uncertainty and loss of control was found as a 
main psychological challenge for the xenograft recipients 
[20].
A study in Mexico with ten adolescents with diabetes 
who received porcine islet cells was published in 2005 
and included interviews and questionnaires [9]. The islet 
recipients reported having no serious concerns regarding 
infectious diseases or identity issues. Their main motiva-
tion was to reduce the required injections, not only for 
health reasons, but also to avoid unpleasant attitudes 
from their peers. The increased autonomy allowed more 
time for other things and let them enjoy foods and bev-
erages, which they had to refrain from before. The islets 
were perceived as a drug rather than a graft. The recipi-
ents reported an improved quality of life, which reversely 
turned into higher depression scores after the graft lost 
its functionality. Recipients in which the islet cells did not 
respond reacted with frustration.
Informed consent to xenotransplantation
An informed consent to xenotransplantation needs to 
encompass all aspects that also have to be covered for an 
allotransplantation. In addition, it must contain the two 
aspects mentioned above: that the organ or tissue comes 
from an animal (which may implicate certain psychologi-
cal challenges) and the risk of transmitting zoonoses.
In a consensus statement, the International Xenotrans-
plantation Association (IXA) outlined structure and 
content of an informed consent form for a xenotrans-
plantation [4]. Based on statements of the Nuffield Coun-
cil on Bioethics [21] and the U.S. Department of Health 
and Human Services Secretary’s Advisory Committee on 
Xenotransplantation [22], the statement identifies twelve 
major topics that should be covered in the informed con-
sent process:
 1. Identification of the study as medical research and 
statement of voluntary enrolment
 2. Description of the patient’s prospective medical 
condition
 3. Portrayal of possible treatment choices/alternatives
 4. Participation information (inclusion and exclusion 
criteria, randomization, etc.)
 5. Study procedures (screening visits, assessments, 
medications, etc.)
 6. Information about potential risks (infections, quar-
antine, failure rates, matters of quality-of-life, etc.)
 7. Post-protocol responsibilities of the patient (moni-
toring, education of family members and partners, 
agreement to autopsy, etc.)
 8. Potential benefits
 9. Costs, compensation
 10. Confidentiality
 11. Contact information
 12. Statement of right of withdrawal from the study
Special features of the consent process for a xenotrans-
plantation are the post-protocol responsibilities (point 
7). This is due to the possibility of infectious diseases 
that may be transmitted from animals to humans. The 
statement also identifies ten responsibilities of xenograft 
recipients: “(i) regular post-clinical research check-ups; 
(ii) informing researchers of future changes of address/
contact numbers; (iii) timely reporting of all unexplained 
illnesses; (iv) following present and updated behav-
ioural guidelines with respect to exchanges of body flu-
ids with intimate contacts; (v) no future donations of 
blood, sperm, or other body fluids or tissues; (vi) autopsy 
at time of death; (vii) education of family members and 
intimate contacts about their need to take precautions 
associated with infectious disease risks—that includes 
offered educational assistance from the research team; 
(viii) disclosure to future healthcare providers that sub-
jects have received a xenotransplantation product; (ix) 
willingness to accept possible isolation and possible 
quarantine if necessary for public health; and (x) arrange-
ments for assistance in meeting future responsibilities 
should the subject lose decision-making capacity” [4]. 
There are some limitations in the withdrawal from the 
study according to point 12. Participants can withdraw 
from the study, but cannot circumvent the post-proto-
col responsibilities. This conundrum can be resolved 
by informing the participants in the informed consent 
that “they are waiving any right to withdraw from their 
later surveillance responsibilities” [4]. As a complete 
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withdrawal of consent is impossible, informed consent is 
turned into “obligatory ‘contractual agreements’”[23].
Methods
Background, sample and model informed consent
In our study, we interviewed seven T1DM patients (see 
Table  1) to assess which requirements would be neces-
sary for them to consider the transplantation of porcine 
islet cells. The hypothetical trial involved the transplanta-
tion of macroencapsulated porcine islet cells as described 
by Ludwig et  al. [24]. While microencapsulation consti-
tutes of single islet clusters which are covered by semi-
permeable (mostly alginate-based) membranes and are 
implanted into the abdomen [25], macroencapsulation 
involves the housing of a whole islet preparation within 
a closed container covered by membrane systems. Upon 
pre-peritoneal implantation, this macroencapsulation 
device, the “bioartificial pancreas device”, is connected to 
subcutaneous fixed ports for external oxygen supply [24].
The participants were recruited via the diabetes outpa-
tient clinic of the University of Munich hospital. For basic 
patient characteristics see Table 1. Before the interviews, 
the study participants confirmed their informed consent 
in a written form.
All methods included in the interview study were car-
ried out in accordance with the Declaration of Helsinki. 
The study received prior ethical approval by the Ethics 
Committee of the Medical Faculty of the Ludwig Maxi-
milian University of Munich (project number 017-12).
To assess potential xenotransplantation recipients’ 
opinions as realistically as possible, we provided the 
interviewees in our study with a model informed con-
sent form for a potential clinical trial of porcine islet cell 
xenotransplantation. It contained all the points, as out-
lined by the IXA, listed above.
The form features details on the operators, funders 
and participating parties of the study, details on con-
tent, objective, structure, circumstances and proceedings 
of the transplantation, potential risks and benefits for 
the patients, and terms and conditions of participation 
(Additional file 1). The entire original form (in German) 
can be accessed upon request from the corresponding 
author.
Data collecting and analysing methods
The interviews were semi-structured and followed a topic 
guide (Additional file 2) consisting of questions regarding 
the patients’ evaluation of xenotransplantation in general, 
assessment  of background, process and implications of 
the study, terms of participation, and feedback regarding 
the model informed consent.
All interviews were conducted at the Institute of Eth-
ics, Theory and History of Medicine in Munich between 
November 2014 and January 2015. The duration of the 
interviews was between 33 and 127  min. The consider-
able variation may be partly caused by different levels of 
scrutiny invested in reading the provided information by 
the participants.
The interviews were transcribed verbatim. The inter-
views were held in German. All quotes from the inter-
views were translated into English by the authors.
The anonymized transcripts were analysed using quali-
tative content analysis [26] which can comprise of vari-
ous techniques of coding, categorizing, or typifying. The 
interviewees’ accounts rendered substantial insights on 
the patients’ hold of their experiences with diabetes and 
their assessments of their living conditions, respectively 
their quality of life. To utilize these descriptions for a 
substantive evaluation of xenotransplantation we decided 
to make use of these passages without applying a coding 
frame from the beginning. To catalyse these accounts in a 
best possible way without restricting them to the points 
stressed in the model consent form we used open cod-
ing as developed by Grounded Theory methodology [27, 
28]. In a second step codes were clustered in categories, 
Table 1 Basic characteristics of the interviewees (names haven been pseudonymized)
Interviewee, age Diabetes history Therapy (history and assessment)
Mr. A (mid 40s) Since adolescence; has used insulin from pigs and cows Very happy with insulin pump; allows for flexibility in his work routine
Mr. B (50) Since birth; has used insulin from pigs and cows Using insulin patch pump; excited about continuous glucose monitor 
(CGM), but not paid for by health insurance
Mrs. C (late 50s) Since 2013 Happy with multiple daily injections (MDI) therapy
Mr. D (30) Since 2009 Using (tethered) insulin pump (due to problems with patch pump); 
appreciates flexibility in virtue of the pump
Mr. E (late 20s) Since 2007 Happy with MDI
Mrs. F (late 40s) Since age 13; has used insulin from pigs and cows Very happy with using insulin pump and CGM
Mrs. G (60) Since age 12; has used insulin from pigs and cows Happy with insulin pump (before pump: often unconscious); occasionally 
additional injections necessary; stent (due to diabetes)
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leading to five key categories that are outlined in the fol-
lowing section.
Results
The aim of the study was to investigate under which 
conditions patients with T1DM would participate in a 
specific trial of islet xenotransplantation and what they 
expect from the informed consent process. One week 
prior to the interviews, we provided the study partici-
pants with a model informed consent form. The form 
included information regarding xenotransplantation in 
general and its implications and possible risks and ben-
efits of the proposed trial. The model informed consent 
form including the description of the trial was based on 
an actual study protocol that has been under evaluation 
for clinical application.
The T1DM patients’ statements on what they con-
sidered relevant for potential trial participation can be 
differentiated into five key categories: therapy-related 
requirements, professional care and supervision, suc-
cessful behaviour and attitude management, granting 
quality of life, and managing control/self-determination 
challenges.
Finally, the participants’ recommendations regarding 
the informed consent form are outlined briefly.
Therapy‑related requirements
The study participants saw porcine xenografts as a last 
option  in the case of failed standard therapies. As long 
as conventional therapeutic strategies work for the inter-
viewees, they reported to have no reason to change it. As 
some had made the experience already of having changed 
from MDI to an insulin pump, they regarded xenotrans-
plantation as a potential alternative at some point in the 
future.
In case of receiving a xenograft, the interviewees con-
sidered it important not to have to rely on immunosup-
pressives (this point is stressed in the patient information, 
but has been spelled out by an interviewee, nevertheless) 
and to be independent from additional insulin.
The kind and frequency of invasive procedures that 
would be necessary for refilling the boxes with the islet 
cells was also reported to be important. Two interviewees 
found it acceptable to have a refill procedure done once a 
year, one interviewee found every two years acceptable, 
and another interviewee found it acceptable to get a refill 
two times a year. If the refills were possible without sur-
gery, e.g. with a syringe, refill procedures would be more 
accepted.
Professional care and supervision
As indicated in the patient information, there would be 
various specialists that are involved in the study: first and 
foremost, the medical staff, and a psychologist for con-
sultations. The interviewees found it important to have 
diabetes and transplant specialists on board; some also 
wanted to involve their general practitioner as someone 
they can trust. Otherwise, trust needs to be established 
between the patient and the physicians in charge, as one 
interviewee stated:
“I think it is very very important that there is some 
relationship of trust, because it really has an impact 
on your life” (Mr. E).
Some participants opted to include a psychological con-
sultant; others mentioned that they would not mind her 
presence. One interviewee would have appreciated psy-
chological support in order to assess whether she was 
mentally prepared for transplantation.
The interviewees also found it important that the 
medical and psychological staff would be present and 
approachable not only for pre-study consultations, but 
also during the study and afterwards, during the post-
trial monitoring. It was seen as important that
“the patients know that they are in good hands; that 
there is a really personal care” (Mr. E).
Furthermore, the potential xenotransplantation patients 
expected transparency from the physicians and consult-
ants in charge. They wanted to be informed regarding the 
current state of research, the functioning of the porcine 
islet cells and physiological implications, as well as possi-
ble worst case scenarios. They found it especially impor-
tant that the consultants are honest regarding potential 
risks and benefits involved, as well as about possible 
alternative treatments and their respective prospects.
Having met various physicians over the course of her 
life, one interviewee emphasized her appreciation for 
those who were able to alleviate someone’s fears and treat 
someone as a human.
In general, most interviewees trusted the scientific and 
clinical staff, also when it comes to making sure that there 
won’t be any risks regarding infections or other diseases.
Successful behaviour and attitude management
The interviewees figured that transplantation would 
require changes or adjustments of beliefs or opinions 
they had held or in the routines they had followed in the 
past. At the same time some issues were not regarded as 
problematic.
None of the interviewees considered the use of animals 
as ethically problematic. Some had already used insulin 
from pigs or cows in the past. As pigs are used for meat 
production, their use as organ source posed no prob-
lem to the interviewees, while the use of other animals, 
e.g. protected species, was considered unacceptable. 
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Acknowledging meat consumption in our society puts 
xenotransplantation into perspective, as one interviewee 
recognized:
“Eventually, I think, that’s a societal question: we eat 
a lot of meat and do not think about it” (Mr. E).
Recalling the time they used pig insulin, one interviewee 
reported:
“I was feeling way better due to the insulin, therefore 
I didn’t think about it” (Mrs. F).
While the use of animals as such is not seen as a problem, 
the proportionality between the number of organ sources 
and recipients was questioned, as one islet filling would 
require about three to four pigs.
“Just because of one life, which can be perpetuated 
in some other way, three pigs need to die. That lies 
heavy on my shoulders” (Mr. A).
Under these conditions, the interviewee would expect 
the islet cells to last for at least ten years.
The interviewees also did not regard islet cells as play-
ing a relevant role for the recipient’s identity. Rather, they 
found it important to have a stable living environment 
that can accustom required changes in the patient’s life 
and that would allow them to cope with possible hard-
ships. Deemed important in that regard was “being set-
tled”, meaning having a stable place to live and having 
completed one’s family planning.
One interviewee would have to change her advance 
directive to allow for an autopsy, which she would be 
willing to do in case of study participation.
For the interviewees, one of the most relevant points 
would be whether the xenotransplantation and its 
requirements can be integrated into one’s daily routine 
and everyday life. One interviewee had concerns regard-
ing her workplace,  in that  she would have to be absent 
from work for a few days every year for the refill proce-
dures. Others saw the frequent act of connecting the 
device to the oxygen supply as quite obstructive, while 
others saw no difference to what they had been doing 
thus far:
“I need to do measurements every day; I need to do 
injections every day, anyway. That’s a ritual you get 
used to” (Mrs. C).
Interviewees sought more detailed information regarding 
how the xenotransplantation would affect their everyday 
life:
“How long do I have to refrain from sports? How long 
do I have to stay away from the sauna? Do I need 
to be cautious about my diet or about some sports 
activities” (Mr. D)?
Granting quality of life
There are several aspects affecting one’s quality of life 
that played a role in the interviewees’ accounts. For once, 
their mobility needs to be maintained. Quarterly check-
ups were still regarded as manageable by most interview-
ees.  Having  diabetes, the interviewees reported they 
were used to frequent or regular visits at their physicians. 
According to one interviewee, participating in xenotrans-
plantation would require living near the study centre, as 
the frequent visits would make long-distance travel quite 
strenuous. As long as changing one’s place of living is not 
a matter of concern, it did not appear to be a problem for 
the interviewees. Nevertheless, one would need to think 
about it before opting for a xenotransplantation.
Also relevant to one’s mobility is the oxygen device, 
which needs to be plugged in every 24 h. Some consid-
ered this to be unproblematic, while others saw it as a 
major infringement on their mobility. The device should 
be as small as possible to keep the mobility restrictions to 
a minimum.
One interviewee who liked bicycling and mountain-
eering ruled out the possibility of an artificial pancreas 
device, because according to the informed consent (IC) 
form there would be too many requirements prevent-
ing him from doing these activities and therefore, he 
would not choose a xenotransplantation. Especially for 
those who enjoy traveling, hiking, bicycling, or camp-
ing, the dependency on electricity (charging the oxygen 
device) or on devices that use batteries, which need to be 
changed or recharged, could compromise these activities.
Additional time restrictions that would be caused were 
mentioned: Having to do measurements every four hours 
and going to the hospital for frequent check-ups during 
the monitoring phase would add to the fair amount of 
time that xenotransplantation and pre-study consulta-
tions already require.
Also, comfort needs to be granted. One interviewee 
ruled out carrying an islet box as he was used to sleeping 
on his stomach and saw a box as compromising his sleep-
ing habits and hence his quality of life.
A further requirement is to make sure that the 
xenotransplantation will not affect quality of life in terms 
of career or family. One interviewee saw the possibility of 
quarantine as something that could affect his job security, 
because “you cannot go to your employer saying ‘Listen, I 
am gonna be in quarantine for three weeks!’” (Mr. D).
He also did not want his employer to know about his 
diabetes in the first place, “because you are being pigeon-
holed […] until your employer recognizes […] that you 
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are working just as good as a perfectly healthy person 
does” (Mr. D).
At the same time, sufficient flexibility needs to be 
assured, as work does not always allow for fixed meal 
times, one interviewee stressed. In terms of flexibility, 
the interviewees appreciated the advantage of the insulin 
pump as opposed to pen injections, as they also allow for 
a reduced number of meals a day and hence would allow 
for more balanced and healthier nutrition.
Partners and family may also be affected in case of the 
transmission of xenogeneic infections. Potentially neces-
sary measures, such as being put under quarantine, need 
to be reasonable. That was an exclusion criterion for one 
respondent, as one of her children has a compulsion neu-
rosis. Another interviewee said quarantine would not be 
a possibility for his partner, as she would lose her job. 
Also other interviewees formulated concerns regarding 
their partners’ jobs. Besides that, no interviewee saw any 
problems regarding their partner’s or family’s dissent in 
case they should want xenotransplantation.
A precondition, of course, is that family planning has 
been completed, as participation in the study requires 
refraining from reproduction for at least five years 
after the transplantation. For most interviewees, fam-
ily planning was off the table already. For one younger 
interviewee, it was said to be okay to refrain from repro-
duction for up to five years, but he would not be willing 
to commit to give it up completely. Another interviewee 
had plans to start a family and, consequently, ruled out 
xenotransplantation.
Apart from the workplace, the acceptance of xenotrans-
plantation by society was not regarded as a problem for 
the interviewees, as they have not experienced discrimi-
nation in any way due to their diabetes. Where or how a 
diabetic gets his daily insulin is not necessarily known by 
others anyway, one interviewee explained.
Interviewees also requested to have some kind of secu-
rity  in case the xenogeneic therapy fails, financially and 
medically. There would need to be something you can fall 
back on in terms of therapy and some kind of insurance 
that covers expenses that may arise from the transplanta-
tion or its failure.
Managing control/self‑determination challenges
A final cluster of issues raised was control and freedom of 
decision. What interviewees disliked about the islet box 
was that any control or possibility of regulation would be 
out of their hands, unlike in the case of the insulin pump, 
for example. If the device, the bioartificial pancreas, mal-
functions and releases too much insulin at once, you 
would not be able to regulate. At the same time, the box 
is supposed to be optically unobtrusive.
The control aspect is also prevalent given the 
unknown risks and potential infections. One inter-
viewee was very sceptical  about  xenotransplantation. 
As she had been living with her diabetes for most of her 
life and has managed to deal with it, the prospect of any 
risks accompanying the transplantation, in particular 
regarding unknown viruses or anything of that kind, 
appeared appalling to her.
“I’ll have that transplantation and may catch 
something that is unfamiliar. I would be a real 
guinea pig. For ME personally, I don’t have a good 
feeling about it” (Mr. F).
One interviewee related this uncertainty to the ethical 
issue of putting others at risk, given the possibility of 
infectious diseases:
“this could be a reason to say ‘No, I can’t do it’ out 
of responsibility for humankind” (Mrs. G).
To maintain as  much freedom of choice as possible 
interviewees deemed it to be necessary to get all the 
knowledge necessary or available when it comes to the 
medical procedure and its potential risks and benefits, 
as well as possible alternatives.
However, given the complexity of xenotransplanta-
tion interviewees were aware that they cannot make 
informed decisions by themselves:
“I am the one who gets surgery and who does this 
transplantation, but just the risk of infections of 
some viruses where it is not clear if they exist or 
not, are—I find—reasons enough to say: This is 
something where you cannot make a decision on 
your own” (Mr. E).
One interviewee stressed that the privacy of the deci-
sion-making should be preserved. The interviewees 
therefore did not appreciate public discussions on mat-
ters like xenotransplantation, as it could impede one’s 
decision-making.
Lastly, they would have appreciated to be involved 
when it comes to the allocation of transplants, more 
specifically regarding who is supposed to get human 
transplants and who is supposed to get animal trans-
plants. However, some interviewees regarded this sim-
ply as something that is removed from their discretion. 
Some interviewees also did not categorically prefer 
human over animal islets. They would opt for what is 
available and the least complicated procedure.
Only one person would seriously consider xenotrans-
plantation, as the insulin pump had started to fail. 
Therefore, she was looking for alternatives as a matter 
of survival. For the other interviewees, their degree of 
independence was a priority in that their health was 
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already covered by their respective therapies. One 
interviewee, reflecting on his history of having used 
various devices for measuring blood sugar and injecting 
insulin, stated:
“I went through all these things; hence I’m thor-
oughly a diabetic person. Whereas […] I would say, 
I’m healthy and have diabetes, by the way” (Mr. B).
Paraphrasing this interviewee, he was considering him-
self a “healthy diabetic”. However, he had experienced 
quite the reverse in the past when he had to take metic-
ulous blood measurements for his health insurance 
provider:
“THAT made me a diabetic again” (Mr. B).
Regarding the potential infringements because of the 
xenotransplantation (4  h measurements, 24  h oxygen 
supply, no CGM,  jeopardising one’s work life), he came 
to the conclusion: “I’ll be treated to death. With that I’ll 
DEFINITELY be a living dead diabetic” (Mr. B).
The prospect of still having to inject insulin even with 
an bioartificial pancreas device would be an exclusion 
criterion for some, as there would be no gain in freedom 
or independence. A central requirement for accepting an 
islet xenotransplantation would be insulin independence.
Assessment of the informed consent form
As mentioned above, interviewees sought comprehensive 
information to grant self-determined decision-making:
“The patient has to decide, whether he wants this 
or that. He should have a FREE choice and COM-
PLETE information” (Mr. B).
Hence, some more detailed information should be 
included in the informed consent form. For example:
• It should be stated that family planning should be 
completed or off the table.
• Alternative therapies, such as stem cell transplanta-
tion, should be discussed.
• Detailed information should be provided on the 
functioning of the Langerhans islets.
• Data of previous or similar studies should be given.
Information that was not present in the informed con-
sent form includes the following points:
• The life expectancy of the cells and possible conse-
quences: How long do islet cells survive in the box? 
What happens when cells die in the box? Do they 
have a negative impact on your body?
• Maintaining the devices: How do I keep the devices 
sterile (when changing the inside of the box, the oxy-
gen supply cables and plugs)? What effort does that 
take? What happens when there is no oxygen supply 
for more than 24 h?
• Behaviour in case of emergencies: What about 
when I have high blood pressure (in that you need 
to refrain from blood-thinning medication)? What 
happens when a disease is discovered, but cannot be 
cured or turns out to be risky? What happens when I 
have low blood sugar?
• Alternatives: Why not use a continuous glucose 
monitor (CGM) instead of doing measurements 
every four hours?
• Monitoring: Why is it necessary to have check-
ups even after you stopped using the islet cells (i.e. 
beyond the five years threshold)?
• Coverage and insurance: What expenses and costs 
will become necessary after the study? For how long? 
Compensation of partners or family or others in case 
of quarantine?
• What are the everyday life restrictions, e.g. how long 
until I can do sports again, sauna, etc., or restrictions 
in nutrition?
One interviewee stated that a detailed IC would pro-
vide sufficient information for her. Other interviewees 
stressed the importance of oral consultations as they 
prefer face-to-face meetings over written forms. The 
consultation was also deemed important to get a better 
understanding and because the form is quite objective 
and impersonal: one interviewee is “not sure, if this form 
can relieve one’s FEARS” (Mr. E). Therefore, the per-
sonal consultation was seen to be vital in this regard in 
particular.
Because of the limited capacity to process or register 
spoken words, multiple consultations and repeating the 
challenges of the transplantation were regarded as being 
necessary in order to make sure that the decision of the 
patient is really well informed.
Interviewees also suggested some change of words and 
formulations for reasons of clarity and comprehension.
Discussion
Serious health-related reasons are the prerequisite for 
persons with diabetes to consider the transplantation of 
porcine islet cells. Otherwise, priority is given to main-
tain their quality of life with the current therapy. Poten-
tial xenotransplantation patients do consider ethical 
and social aspects like animal use and communicable 
diseases, but personal health and well-being becomes 
more important in light of the impact of their illness. This 
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prioritization reflects the findings from Idvall [16] and 
Lundin [18, 19].
Every diabetes therapy should retain the “healthy dia-
betic” as a central notion of self-understanding. Main-
taining this identity is deemed important by potential 
xenotransplantation patients. Another interviewee stated 
that diabetes “simply belongs to me” (Mrs. F). The oppo-
site would be the “diabetic patient”, where the diabetes 
leads to a noticeable infringement of one’s freedom and 
independence. To be dependent on something, in this 
case a particular therapy and technology, presupposes 
not having to worry too much about things.
Having diabetes, the interviewees are familiar and used 
to therapeutic consultations and procedures and have 
gathered a lot of experience in interacting with medical 
staff and dealing with medical and health-related issues. 
Due to this familiarity, most interviewees display a great 
level of trust in medicine and physicians.
Trust and transparency are essential to bridge the gap 
between autonomy and health. Being aware of the fact 
that you cannot fully assess the risks of this procedure 
and need to rely on others, you have to make concessions 
in terms of control and self-determined decision-making.
One interviewee also acknowledged that the decision 
for or against xenotransplantation cannot be up to one 
alone. In this case he had his partner in mind, but it also 
applies to other people. This turns the matter into a soci-
etal decision. Xenotransplantation is seen as a societal 
question also when it comes to the use of animals for our 
sake. This question is answered in favour of xenotrans-
plantation, as we already accept the killing of animals for 
food production.
Given that in the hypothetical xenotransplantation trial 
that was portrayed in this study the islet cells would be 
contained in a box, the participants expressed no uncer-
tainty regarding the placement of the cells like in the 
studies by Lundin. However, the potential transplant 
recipients did not know if cells are dying and what the 
consequences would be. As they do not have access to 
the islet box, they also missed the control over how the 
cells work. Like in other studies [11–13], the interview-
ees also expected insulin independence from an artificial 
pancreas device and not having to inject additional insu-
lin themselves. Hence, there are further issues concern-
ing the loss of control.
The interviewees of this study assumed that the source 
of the cells, i.e. pigs, would not bother them. Instead, 
psychological problems may arise from difficulties with 
the treatment, challenges being imposed upon fam-
ily and partners, or even the stigmatization as a person 
with diabetes. The risk of the transmission of a xenoge-
neic infection caused worries among some interview-
ees, which is similar to other studies [11, 14]. However, 
our interviewees were mainly concerned with possible 
quarantine for family and partners. As the psychologi-
cal problems raised by Abalovich [10] are not elaborated, 
it is hard to draw comparisons. In the case that identity 
crises may occur due to the knowledge that animals are 
the organ sources, as in the study by Stadlbauer [14], our 
interviewees did not envisage them.  Also in contrast to 
that, stigmatization by friends and family is not feared, 
but may become relevant for some at the workplace.
As indicated at the beginning, potential patient inter-
viewees are primarily concerned with their own health. 
While they take into account the consequences for their 
partners and family, worries regarding public health are 
not seen as their responsibility. This task lies upon soci-
ety or the government [23].
Instead, what clearly comes to the fore in these inter-
views and what is hardly reflected in the literature so 
far, are the concerns regarding the impact of xenotrans-
plantation on the interviewees’ routine and everyday life. 
These include whether they will be able to function in the 
same way, whether they will be able to pursue sports and 
outdoor activities that they are used to and which they 
cherish, whether they will be able to perform their jobs 
in a normal manner, or if they will need to change their 
eating habits.
Limitations
The study contains several limitations. First of all, the 
study involves only a small number of participants. As the 
reading of the model informed consent form prior to the 
interviews was a precondition for participation, recruit-
ment turned out to be more difficult than expected. At 
the end, only seven participants were willing to complete 
that task and participated in the study. While the small 
sample size is not in general at odds with the methodo-
logical standards of qualitative research, it may some-
what reduce the generalizability of our findings.
The sample of the study consists of persons that vary in 
many respects, in particular regarding their age and the 
progression of their diabetes. More detailed research with 
respective study groups is encouraged. As xenotransplan-
tation research often involves genetically modified pigs, 
patients’ opinions regarding this important aspect should 
also be assessed. While this study is focused on macroen-
capsulated cell transplantation, alternative technologies, 
i.e. transplantation of free or microencapsulated islet 
cells [17], also ought to be discussed. These rather spe-
cific studies can be complemented with further studies 
on xenotransplantation in general as well as with studies 
assessing public opinion on xenotransplantation [29].
Given the hypothetical character of the scenario dis-
cussed, the assessment of the study participant’s account 
serves best to adjust future informed consent forms and 
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procedures accordingly and must not be overestimated in 
terms of actual consequences of xenotransplantation for 
the patients.
Conclusions
In conclusion, it can be stated that for porcine islet cell 
transplantation to become a sustainable therapy for 
diabetes, it has to guarantee the “healthy diabetic”. The 
patient should be able to continue living her life without 
having to sustain too many infringements and restric-
tions. Where measures necessary for the procedure fit 
within the patients’ regular diabetes regime of check-
ups, measurements, injections, etc., a xenotransplan-
tation is conceivable. When additional requirements 
are due and limitations on things of daily life that are 
appreciated by the patients are expected, xenotrans-
plantation becomes problematic.
Given the current requirements, most persons with 
diabetes would consider xenotransplantation only as 
ultima ratio. A comprehensive and comprehensible 
informed consent form needs to meet all requirements 
in order to contribute to the potential participants’ 
decision-making and to make it as well informed and 
autonomous as possible.
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